it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
.
�long delays can put people under incredible stress at an already difficult time and could also mean that someone�s health could take a turn for the worse.
.
